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sion, occurs over time. Down-regulation of gene expression was 
postulated to explain the disappearance of human adenosine deami-
nase from dermal equivalent grafts containing rat fibroblasts trans-
duced with the human adenosine deaminase gene, as vector 
sequences were detected for months in the grafts after human 
adenosine deaminase levels had fallen [12]. The promoter that 
drives transcription of the introduced gene also may be a key factor 
in determining long-term expression in vivo. Scharfmann et al [21] 
demonstrated prolonged expression (60 d) of a /3-galactosidase 
gene linked to a housekeeping gene promoter, dihydrofolate 
reductase, compared with that linked to a cytomegalovirus pro-
moter. In the recombinant retrovirus used in our study, the 5' 
long-terminal-repeat promoter directs transcription of the hTf 
gene. Whereas bone marrow cells transduced with retroviral 
transcripts encoding the human adenosine deaminase gene linked to 
the long-terminal-repeat promoter have expressed this gene in vivo 
for up to 5.5 months [22], expression of long-terminal-repeat-
driven genes in fibroblasts for longer than 2 months in vivo has not 
been reported [21,23]. 
In conclusion, we have analyzed a model system of gene therapy 
to correct deficiencies of plasma proteins. Important features 
demonstrated with this model include selection of a clone of cells 
producing high levels of the introduced gene product, expansion of 
this clone for use in the transplanted dermal matrices, consistent 
gene expression for over 18 weeks (130 d), and correlation of 
plasma levels with the size of the developing tumors containing the 
genetically modified cells. These findings support the hypothesis 
that autologous fibroblasts with a stable transgene that is transcrip-
tionally active are a reasonable target for genetic modification to 
correct deficiencies in plasma proteins. It also seems likely that such 
a system could be used to correct localized inherited diseases of the 
skin, with a trans gene product being delivered in a paracrine 
fashion. 
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ANNOUNCEMENT 
The 44th Annual Symposium on the Biology of Skin, entitled "Skin Cancer: Pathomechanisms. 
Epidemiology and Clinical Manifestations, and New Approaches to Therapy," will be held July 
11-15, 1995 at Snowmass Village, Colorado. 
This meeting will provide a comprehensive review of the cellular and molecular biology of 
carcinogenesis, the biology of skin cancers, and modern approaches to treatment. 
Formal presentations by invited speakers, invited poster presentations, and free poster presentations 
will be included. 
Abstracts for the free poster session should be submitted by May 15, 1995 on SID or ESDR abstract 
forms to: 
David A. Norris, M.D. 
44th Annual Symposium on the Biology of Skin 
Box B 144 Department of Dermatology 
University of Colorado School of Medicine 
4200 East Ninth Avenue 
Denver CO 80262. 
